We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Executives from nine pharmaceutical companies have agreed, at the request of UN Secretary-General Kofi Annan, to review the prices of their antiretroviral (ARV) drugs to make them more affordable and accessible.
GlaxoSmithKline (GSK) has reported a high immune response for it's pandemic flu vaccine with a low dose of antigen the foreign substance that prompts the body to make an immune response.
India's Department of Chemicals and Fertilizers may soon finalize a decision on introducing quality criteria for bulk procurement of medicines by government institutions.
Fresenius Medical Care ("the Company"), the world's largest provider of Dialysis Products and Services, has received regulatory approval from Germany's Federal Institute for Drugs and Medical Devices (Bundesinstitut für Arzneimittel und Medizinprodukte) for a new phosphate binding agent.
The Debiopharm Group (Debiopharm), a global independent biopharmaceutical development company specialising in oncology and serious medical conditions filed a French marketing authorisation application (MAA) for Sanvar in the treatment of patients with esophageal variceal bleeding (EVB).
Molecular diagnostics company Tepnel Life Sciences PLC said it has signed an agreement to provide analytical chemistry and microbiological quality monitoring services to pharmaceuticals giant Pfizer Inc for an undisclosed sum.
The largest international producer of human vaccines, pharmaceutical company Sanofi Pasteur, is interested in strategic investment in Croatian Immunology Bureau d.d., which operated with losses for the past few years, 'CT' reports.
Onyx Pharmaceuticals Inc. and Bayer Pharmaceuticals Corp. have received the European Commission's authorization to market their kidney cancer drug, the two companies announced.
India's leading drug maker Ranbaxy Laboratories Ltd. is facing the legal music from a dozen odd multinational companies on at least 11 of its generic molecules in its pursuit to conquer the global generic market through the Para IV challenge route.